The stock market was up and down with Trump tariff fears in focus. Palantir led big earnings winners. Google and Amazon were ...

Much of the slack seems to have been taken up by Huawei; the Chinese tech giant ... period wasn’t a merry one for Apple. Last week, market research firm IDC reported that global iPhone unit ...

Stock market crash: Consumer durables, real estate, and mid and small cap financial services stocks pulled down the stock market during the early trading hours Stock market crash: The stock market ...

No president has ever inherited a pricier stock market. Yesterday ... it can be easily tripped up by short-term shock events that disrupt corporate earnings. For example, lockdowns during the ...

But India has lost a step, revealing its vulnerabilities even as it moves up the global rankings. The stock market, which soared for years, has just erased the past six months of gains.

When looking back at the event in totality, here’s my take on who and what saw their stock go up or down after UFC 311. I don’t want to beat a dead horse, but take a look at some of these ...

"The first thing that happened in the stock market since the election was the market rally with risk assets going up and interest rates going down ... market has moved "sideways" over the past ...

The stock market chugged along this week after Wall Street finally got good news on inflation. The S&P 500 is up 1.2% ... on the 30-year Treasury note was down to 4.84% on Friday after spiking ...

Stock Market Today: Dow Jones Climbs 0.8% While Nasdaq ... The Evidence Is Piling Up, and Here's What It Says. Charlie Munger Praised Buffett's $20 Billion 'No-Brainer' Investment In Japan ...

Stock-market investors are turning jittery over something which has apparently happened only two times in the bond market since the early 1980s: The 10-year Treasury yield has jumped by about as ...

Stock market today: The BSE benchmark surged 318.74 points or 0.42 per cent to reach 77,042.82, after touching an intraday peak of 77,319.50, marking a rise of 595.42 points or 0.77 per cent.

ABBV continues to claim 72% of the adalimumab market in the U.S. as of November, even as its biosimilars have gained ground, claiming 23% of the market, up from 2% about a year ago.